

Paul D Bieniasz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3529523/publications.pdf>

Version: 2024-02-01

174
papers

33,318
citations

5261

83
h-index

4770

169
g-index

220
all docs

220
docs citations

220
times ranked

31510
citing authors

#	ARTICLE	IF	CITATIONS
1	A diverse range of gene products are effectors of the type I interferon antiviral response. <i>Nature</i> , 2011, 472, 481-485.	13.7	2,054
2	Convergent antibody responses to SARS-CoV-2 in convalescent individuals. <i>Nature</i> , 2020, 584, 437-442.	13.7	1,742
3	Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. <i>Nature</i> , 2008, 451, 425-430.	13.7	1,618
4	Evolution of antibody immunity to SARS-CoV-2. <i>Nature</i> , 2021, 591, 639-644.	13.7	1,355
5	Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. <i>ELife</i> , 2020, 9, .	2.8	1,239
6	mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. <i>Nature</i> , 2021, 592, 616-622.	13.7	1,232
7	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. <i>Nature</i> , 2007, 446, 801-805.	13.7	1,082
8	Structures of Human Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of Antibodies. <i>Cell</i> , 2020, 182, 828-842.e16.	13.5	724
9	HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. <i>Nature Medicine</i> , 2001, 7, 1313-1319.	15.2	676
10	Vaccine Breakthrough Infections with SARS-CoV-2 Variants. <i>New England Journal of Medicine</i> , 2021, 384, 2212-2218.	13.9	647
11	Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection. <i>Nature</i> , 2021, 595, 426-431.	13.7	610
12	Tetherin Inhibits HIV-1 Release by Directly Tethering Virions to Cells. <i>Cell</i> , 2009, 139, 499-511.	13.5	517
13	Measuring SARS-CoV-2 neutralizing antibody activity using pseudotyped and chimeric viruses. <i>Journal of Experimental Medicine</i> , 2020, 217, .	4.2	503
14	HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. <i>Nature</i> , 2012, 492, 118-122.	13.7	463
15	MX2 is an interferon-induced inhibitor of HIV-1 infection. <i>Nature</i> , 2013, 502, 563-566.	13.7	445
16	HIV Restriction Factors and Mechanisms of Evasion. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2012, 2, a006940-a006940.	2.9	421
17	Intrinsic immunity: a front-line defense against viral attack. <i>Nature Immunology</i> , 2004, 5, 1109-1115.	7.0	396
18	Tetherin-Driven Adaptation of Vpu and Nef Function and the Evolution of Pandemic and Nonpandemic HIV-1 Strains. <i>Cell Host and Microbe</i> , 2009, 6, 409-421.	5.1	391

#	ARTICLE	IF	CITATIONS
19	Enhanced SARS-CoV-2 neutralization by dimeric IgA. <i>Science Translational Medicine</i> , 2021, 13, .	5.8	379
20	Divergent retroviral late-budding domains recruit vacuolar protein sorting factors by using alternative adaptor proteins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 12414-12419.	3.3	375
21	Plasma Neutralization of the SARS-CoV-2 Omicron Variant. <i>New England Journal of Medicine</i> , 2022, 386, 599-601.	13.9	371
22	Cyclophilin A modulates the sensitivity of HIV-1 to host restriction factors. <i>Nature Medicine</i> , 2003, 9, 1138-1143.	15.2	362
23	Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. <i>Journal of Virology</i> , 2009, 83, 1837-1844.	1.5	347
24	Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5 α . <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 10774-10779.	3.3	345
25	CG dinucleotide suppression enables antiviral defence targeting non-self RNA. <i>Nature</i> , 2017, 550, 124-127.	13.7	336
26	Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies. <i>Nature Communications</i> , 2021, 12, 4196.	5.8	332
27	Nef Proteins from Simian Immunodeficiency Viruses Are Tetherin Antagonists. <i>Cell Host and Microbe</i> , 2009, 6, 54-67.	5.1	324
28	Plasma Membrane Is the Site of Productive HIV-1 Particle Assembly. <i>PLoS Biology</i> , 2006, 4, e435.	2.6	299
29	Imaging the biogenesis of individual HIV-1 virions in live cells. <i>Nature</i> , 2008, 454, 236-240.	13.7	290
30	Antibody potency, effector function, and combinations in protection and therapy for SARS-CoV-2 infection in vivo. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	283
31	Species-Specific Activity of HIV-1 Vpu and Positive Selection of Tetherin Transmembrane Domain Variants. <i>PLoS Pathogens</i> , 2009, 5, e1000300.	2.1	273
32	APOBEC3G Incorporation into Human Immunodeficiency Virus Type 1 Particles. <i>Journal of Virology</i> , 2004, 78, 12058-12061.	1.5	264
33	Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002, 99, 11914-11919.	3.3	261
34	Reconstitution of an Infectious Human Endogenous Retrovirus. <i>PLoS Pathogens</i> , 2007, 3, e10.	2.1	249
35	Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. <i>EMBO Journal</i> , 1998, 17, 7056-7065.	3.5	245
36	An Interferon- α -Induced Tethering Mechanism Inhibits HIV-1 and Ebola Virus Particle Release but Is Counteracted by the HIV-1 Vpu Protein. <i>Cell Host and Microbe</i> , 2007, 2, 193-203.	5.1	241

#	ARTICLE	IF	CITATIONS
37	HIV-1 Vpu Promotes Release and Prevents Endocytosis of Nascent Retrovirus Particles from the Plasma Membrane. <i>PLoS Pathogens</i> , 2006, 2, e39.	2.1	239
38	Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. <i>Nature</i> , 2021, 600, 517-522.	13.7	239
39	Imaging the interaction of HIV-1 genomes and Gag during assembly of individual viral particles. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 19114-19119.	3.3	233
40	Longitudinal Serological Analysis and Neutralizing Antibody Levels in Coronavirus Disease 2019 Convalescent Patients. <i>Journal of Infectious Diseases</i> , 2021, 223, 389-398.	1.9	233
41	Role of ESCRT-I in Retroviral Budding. <i>Journal of Virology</i> , 2003, 77, 4794-4804.	1.5	231
42	Affinity maturation of SARS-CoV-2 neutralizing antibodies confers potency, breadth, and resilience to viral escape mutations. <i>Immunity</i> , 2021, 54, 1853-1868.e7.	6.6	230
43	Natural Variation in Vif: Differential Impact on APOBEC3G/3F and a Potential Role in HIV-1 Diversification. <i>PLoS Pathogens</i> , 2005, 1, e6.	2.1	226
44	Human Tripartite Motif 5'± Domains Responsible for Retrovirus Restriction Activity and Specificity. <i>Journal of Virology</i> , 2005, 79, 8969-8978.	1.5	223
45	Restriction of multiple divergent retroviruses by Lv1 and Ref1. <i>EMBO Journal</i> , 2003, 22, 385-394.	3.5	216
46	Global Changes in the RNA Binding Specificity of HIV-1 Gag Regulate Virion Genesis. <i>Cell</i> , 2014, 159, 1096-1109.	13.5	216
47	Identification of Interferon-Stimulated Genes with Antiretroviral Activity. <i>Cell Host and Microbe</i> , 2016, 20, 392-405.	5.1	215
48	Dynamics of ESCRT protein recruitment during retroviral assembly. <i>Nature Cell Biology</i> , 2011, 13, 394-401.	4.6	198
49	Increased memory B cell potency and breadth after a SARS-CoV-2 mRNA boost. <i>Nature</i> , 2022, 607, 128-134.	13.7	197
50	HECT ubiquitin ligases link viral and cellular PPXY motifs to the vacuolar protein-sorting pathway. <i>Journal of Cell Biology</i> , 2005, 168, 89-101.	2.3	184
51	Independent genesis of chimeric TRIM5-cyclophilin proteins in two primate species. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 3563-3568.	3.3	183
52	Cyclophilin Interactions with Incoming Human Immunodeficiency Virus Type 1 Capsids with Opposing Effects on Infectivity in Human Cells. <i>Journal of Virology</i> , 2005, 79, 176-183.	1.5	180
53	Extreme Genetic Fragility of the HIV-1 Capsid. <i>PLoS Pathogens</i> , 2013, 9, e1003461.	2.1	178
54	Multiple Blocks to Human Immunodeficiency Virus Type 1 Replication in Rodent Cells. <i>Journal of Virology</i> , 2000, 74, 9868-9877.	1.5	176

#	ARTICLE	IF	CITATIONS
55	The Cell Biology of HIV-1 Virion Genesis. <i>Cell Host and Microbe</i> , 2009, 5, 550-558.	5.1	175
56	High genetic barrier to SARS-CoV-2 polyclonal neutralizing antibody escape. <i>Nature</i> , 2021, 600, 512-516.	13.7	174
57	Analysis of the Initiating Events in HIV-1 Particle Assembly and Genome Packaging. <i>PLoS Pathogens</i> , 2010, 6, e1001200.	2.1	162
58	Serological Assays Estimate Highly Variable SARS-CoV-2 Neutralizing Antibody Activity in Recovered COVID-19 Patients. <i>Journal of Clinical Microbiology</i> , 2020, 58, .	1.8	154
59	Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 278-282.	13.7	154
60	A macaque model of HIV-1 infection. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 4425-4429.	3.3	150
61	Host and Viral Determinants of Mx2 Antiretroviral Activity. <i>Journal of Virology</i> , 2014, 88, 7738-7752.	1.5	144
62	SAMHD1-dependent retroviral control and escape in mice. <i>EMBO Journal</i> , 2013, 32, 2454-2462.	3.5	141
63	Generation of Simian-Tropic HIV-1 by Restriction Factor Evasion. <i>Science</i> , 2006, 314, 95-95.	6.0	140
64	A Serpin Shapes the Extracellular Environment to Prevent Influenza A Virus Maturation. <i>Cell</i> , 2015, 160, 631-643.	13.5	137
65	Determination of RNA structural diversity and its role in HIV-1 RNA splicing. <i>Nature</i> , 2020, 582, 438-442.	13.7	136
66	Restriction of Human Immunodeficiency Virus Type 1 by TRIM-CypA Occurs with Rapid Kinetics and Independently of Cytoplasmic Bodies, Ubiquitin, and Proteasome Activity. <i>Journal of Virology</i> , 2005, 79, 15567-15572.	1.5	133
67	Context-Dependent Effects of L Domains and Ubiquitination on Viral Budding. <i>Journal of Virology</i> , 2004, 78, 5554-5563.	1.5	129
68	The RING-CH Ligase K5 Antagonizes Restriction of KSHV and HIV-1 Particle Release by Mediating Ubiquitin-Dependent Endosomal Degradation of Tetherin. <i>PLoS Pathogens</i> , 2010, 6, e1000843.	2.1	129
69	A role for ubiquitin ligases and Spartin/SPG20 in lipid droplet turnover. <i>Journal of Cell Biology</i> , 2009, 184, 881-894.	2.3	120
70	Species-Specific Tropism Determinants in the Human Immunodeficiency Virus Type 1 Capsid. <i>Journal of Virology</i> , 2004, 78, 6005-6012.	1.5	119
71	Human Immunodeficiency Virus, Restriction Factors, and Interferon. <i>Journal of Interferon and Cytokine Research</i> , 2009, 29, 569-580.	0.5	116
72	Tetherin is a key effector of the antiretroviral activity of type I interferon in vitro and in vivo. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 18097-18101.	3.3	112

#	ARTICLE	IF	CITATIONS
73	Envelope-Dependent, Cyclophilin-Independent Effects of Glycosaminoglycans on Human Immunodeficiency Virus Type 1 Attachment and Infection. <i>Journal of Virology</i> , 2002, 76, 6332-6343.	1.5	111
74	HIV-1 Integrase Binds the Viral RNA Genome and Is Essential during Virion Morphogenesis. <i>Cell</i> , 2016, 166, 1257-1268.e12.	13.5	110
75	Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. <i>Nature</i> , 2021, 593, 424-428.	13.7	108
76	Structure of the zinc-finger antiviral protein in complex with RNA reveals a mechanism for selective targeting of CG-rich viral sequences. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 24303-24309.	3.3	106
77	Vpu Binds Directly to Tetherin and Displaces It from Nascent Virions. <i>PLoS Pathogens</i> , 2013, 9, e1003299.	2.1	102
78	Restriction factors: a defense against retroviral infection. <i>Trends in Microbiology</i> , 2003, 11, 286-291.	3.5	100
79	Nuclear pore heterogeneity influences HIV-1 infection and the antiviral activity of MX2. <i>ELife</i> , 2018, 7, .	2.8	100
80	Structural insight into the mechanisms of enveloped virus tethering by tetherin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 18428-18432.	3.3	97
81	Mechanism of HIV-1 Virion Entrapment by Tetherin. <i>PLoS Pathogens</i> , 2013, 9, e1003483.	2.1	97
82	Intrinsic Cellular Defenses against Human Immunodeficiency Viruses. <i>Immunity</i> , 2012, 37, 399-411.	6.6	96
83	Integration target site selection by a resurrected human endogenous retrovirus. <i>Genes and Development</i> , 2009, 23, 633-642.	2.7	95
84	Temporal and spatial organization of ESCRT protein recruitment during HIV-1 budding. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 12211-12216.	3.3	93
85	A Comparative Study of Higher Primate Foamy Viruses, Including a New Virus from a Gorilla. <i>Virology</i> , 1995, 207, 217-228.	1.1	88
86	Comparative analysis of the antiretroviral activity of APOBEC3G and APOBEC3F from primates. <i>Virology</i> , 2006, 349, 31-40.	1.1	88
87	Analysis of memory B cells identifies conserved neutralizing epitopes on the N-terminal domain of variant SARS-Cov-2 spike proteins. <i>Immunity</i> , 2022, 55, 998-1012.e8.	6.6	86
88	Hypermutation of an Ancient Human Retrovirus by APOBEC3G. <i>Journal of Virology</i> , 2008, 82, 8762-8770.	1.5	84
89	Fates of Retroviral Core Components during Unrestricted and TRIM5-Restricted Infection. <i>PLoS Pathogens</i> , 2013, 9, e1003214.	2.1	82
90	Broad cross-reactivity across sarbecoviruses exhibited by a subset of COVID-19 donor-derived neutralizing antibodies. <i>Cell Reports</i> , 2021, 36, 109760.	2.9	80

#	ARTICLE	IF	CITATIONS
91	Human Immunodeficiency Virus Type 1 Matrix Inhibits and Confers Cooperativity on Gag Precursor-Membrane Interactions. <i>Journal of Virology</i> , 2004, 78, 9560-9563.	1.5	79
92	Ubiquitin-dependent virus particle budding without viral protein ubiquitination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 20031-20036.	3.3	77
93	HIV-1-induced AIDS in monkeys. <i>Science</i> , 2014, 344, 1401-1405.	6.0	76
94	Co-option of an endogenous retrovirus envelope for host defense in hominid ancestors. <i>ELife</i> , 2017, 6, .	2.8	75
95	Visualizing HIV-1 Assembly. <i>Journal of Molecular Biology</i> , 2011, 410, 501-511.	2.0	73
96	B cell genomics behind cross-neutralization of SARS-CoV-2 variants and SARS-CoV. <i>Cell</i> , 2021, 184, 3205-3221.e24.	13.5	73
97	HIV/AIDS: in search of an animal model. <i>Trends in Biotechnology</i> , 2007, 25, 333-337.	4.9	72
98	Identification of Human VPS37C, a Component of Endosomal Sorting Complex Required for Transport-I Important for Viral Budding. <i>Journal of Biological Chemistry</i> , 2005, 280, 628-636.	1.6	71
99	Multiple Residues Contribute to the Inability of Murine CCR-5 To Function as a Coreceptor for Macrophage-Tropic Human Immunodeficiency Virus Type 1 Isolates. <i>Journal of Virology</i> , 1998, 72, 1918-1924.	1.5	71
100	Absence of Severe Acute Respiratory Syndrome Coronavirus 2 Neutralizing Activity in Prepandemic Sera From Individuals With Recent Seasonal Coronavirus Infection. <i>Clinical Infectious Diseases</i> , 2021, 73, e1208-e1211.	2.9	65
101	No Evidence of Antibody to Human Foamy Virus in Widespread Human Populations. <i>AIDS Research and Human Retroviruses</i> , 1996, 12, 1473-1483.	0.5	61
102	SIV Nef Proteins Recruit the AP-2 Complex to Antagonize Tetherin and Facilitate Virion Release. <i>PLoS Pathogens</i> , 2011, 7, e1002039.	2.1	59
103	Single-Cell and Single-Cycle Analysis of HIV-1 Replication. <i>PLoS Pathogens</i> , 2015, 11, e1004961.	2.1	58
104	Functional Interchangeability of Late Domains, Late Domain Cofactors and Ubiquitin in Viral Budding. <i>PLoS Pathogens</i> , 2010, 6, e1001153.	2.1	57
105	A Bipartite Late-Budding Domain in Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2003, 77, 12373-12377.	1.5	55
106	Inhibition of HIV-1 Particle Assembly by 2'-5'-Cyclic-Nucleotide 3'-Phosphodiesterase. <i>Cell Host and Microbe</i> , 2012, 12, 585-597.	5.1	54
107	The RNA Binding Specificity of Human APOBEC3 Proteins Resembles That of HIV-1 Nucleocapsid. <i>PLoS Pathogens</i> , 2016, 12, e1005833.	2.1	54
108	Primate Lentivirus Capsid Sensitivity to TRIM5 Proteins. <i>Journal of Virology</i> , 2008, 82, 6772-6777.	1.5	51

#	ARTICLE	IF	CITATIONS
109	Sequences in <i>pol</i> Are Required for Transfer of Human Foamy Virus-Based Vectors. <i>Journal of Virology</i> , 1998, 72, 5510-5516.	1.5	51
110	Multiple, Switchable Protein:RNA Interactions Regulate Human Immunodeficiency Virus Type 1 Assembly. <i>Annual Review of Virology</i> , 2018, 5, 165-183.	3.0	50
111	Replication and single-cycle delivery of SARS-CoV-2 replicons. <i>Science</i> , 2021, 374, 1099-1106.	6.0	49
112	Predictors of Nonseroconversion after SARS-CoV-2 Infection. <i>Emerging Infectious Diseases</i> , 2021, 27, 2454-2458.	2.0	48
113	Selection of Unadapted, Pathogenic SHIVs Encoding Newly Transmitted HIV-1 Envelope Proteins. <i>Cell Host and Microbe</i> , 2014, 16, 412-418.	5.1	47
114	Analysis of the human immunodeficiency virus-1 RNA packageome. <i>Rna</i> , 2016, 22, 1228-1238.	1.6	46
115	Clathrin Facilitates the Morphogenesis of Retrovirus Particles. <i>PLoS Pathogens</i> , 2011, 7, e1002119.	2.1	45
116	Tetherin Promotes the Innate and Adaptive Cell-Mediated Immune Response against Retrovirus Infection In Vivo. <i>Journal of Immunology</i> , 2014, 193, 306-316.	0.4	45
117	Capsid-Dependent and -Independent Postentry Restriction of Primate Lentivirus Tropism in Rodent Cells. <i>Journal of Virology</i> , 2004, 78, 1006-1011.	1.5	43
118	HIV-1 at 25. <i>Cell</i> , 2008, 133, 561-565.	13.5	43
119	Identification of Domains in Gag Important for Prototypic Foamy Virus Egress. <i>Journal of Virology</i> , 2005, 79, 6392-6399.	1.5	41
120	Highly Divergent Lentiviral Tat Proteins Activate Viral Gene Expression by a Common Mechanism. <i>Molecular and Cellular Biology</i> , 1999, 19, 4592-4599.	1.1	40
121	Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations. <i>Nature Immunology</i> , 2021, 22, 1503-1514.	7.0	40
122	Global synonymous mutagenesis identifies cis-acting RNA elements that regulate HIV-1 splicing and replication. <i>PLoS Pathogens</i> , 2018, 14, e1006824.	2.1	37
123	HIV-1 Vpr induces cell cycle arrest and enhances viral gene expression by depleting CCDC137. <i>ELife</i> , 2020, 9, .	2.8	37
124	Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape. <i>ELife</i> , 2021, 10, .	2.8	36
125	No effect of endogenous TRIM5 α on HIV-1 production. <i>Nature Medicine</i> , 2008, 14, 235-236.	15.2	35
126	Origins and Evolution of tetherin , an Orphan Antiviral Gene. <i>Cell Host and Microbe</i> , 2016, 20, 189-201.	5.1	35

#	ARTICLE	IF	CITATIONS
127	Analysis of the Effect of Natural Sequence Variation in Tat and in Cyclin T on the Formation and RNA Binding Properties of Tat-Cyclin T Complexes. <i>Journal of Virology</i> , 1999, 73, 5777-5786.	1.5	35
128	Evidence for Restriction of Ancient Primate Gammaretroviruses by APOBEC3 but Not TRIM5 $\hat{\pm}$ Proteins. <i>PLoS Pathogens</i> , 2008, 4, e1000181.	2.1	33
129	Origin and evolution of the zinc finger antiviral protein. <i>PLoS Pathogens</i> , 2021, 17, e1009545.	2.1	33
130	Effect of DNA Repair Protein Rad18 on Viral Infection. <i>PLoS Pathogens</i> , 2006, 2, e40.	2.1	32
131	Antiretroviral restriction factors. <i>Current Opinion in Virology</i> , 2011, 1, 526-532.	2.6	32
132	Assisted Evolution Enables HIV-1 to Overcome a High TRIM5 $\hat{\pm}$ -Imposed Genetic Barrier to Rhesus Macaque Tropism. <i>PLoS Pathogens</i> , 2013, 9, e1003667.	2.1	32
133	The Betaretrovirus Mason-Pfizer Monkey Virus Selectively Excludes Simian APOBEC3G from Virion Particles. <i>Journal of Virology</i> , 2006, 80, 12102-12108.	1.5	30
134	Adaptation to the Interferon-Induced Antiviral State by Human and Simian Immunodeficiency Viruses. <i>Journal of Virology</i> , 2013, 87, 3549-3560.	1.5	28
135	A single gp120 residue can affect HIV-1 tropism in macaques. <i>PLoS Pathogens</i> , 2017, 13, e1006572.	2.1	28
136	Vesicular Stomatitis Virus Transcription Is Inhibited by TRIM69 in the Interferon-Induced Antiviral State. <i>Journal of Virology</i> , 2019, 93, .	1.5	28
137	Role Of Chemokine Receptors In Hiv-1 Infection And Pathogenesis. <i>Advances in Virus Research</i> , 1999, 52, 233-267.	0.9	27
138	Identification of a receptor for an extinct virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 19496-19501.	3.3	27
139	The aryl hydrocarbon receptor and interferon gamma generate antiviral states via transcriptional repression. <i>ELife</i> , 2018, 7, .	2.8	27
140	Convalescent plasma-mediated resolution of COVID-19 in a patient with humoral immunodeficiency. <i>Cell Reports Medicine</i> , 2021, 2, 100164.	3.3	26
141	Matrix-Induced Inhibition of Membrane Binding Contributes to Human Immunodeficiency Virus Type 1 Particle Assembly Defects in Murine Cells. <i>Journal of Virology</i> , 2005, 79, 15586-15589.	1.5	25
142	VSV-Displayed HIV-1 Envelope Identifies Broadly Neutralizing Antibodies Class-Switched to IgG and IgA. <i>Cell Host and Microbe</i> , 2020, 27, 963-975.e5.	5.1	23
143	HIV-1 matrix-tRNA complex structure reveals basis for host control of Gag localization. <i>Cell Host and Microbe</i> , 2021, 29, 1421-1436.e7.	5.1	22
144	The Case Against Delaying Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) mRNA Vaccine Boosting Doses. <i>Clinical Infectious Diseases</i> , 2021, 73, 1321-1323.	2.9	22

#	ARTICLE	IF	CITATIONS
145	Longitudinal variation in SARS-CoV-2 antibody levels and emergence of viral variants: a serological analysis. <i>Lancet Microbe</i> , The, 2022, 3, e493-e502.	3.4	22
146	Uneven Genetic Robustness of HIV-1 Integrase. <i>Journal of Virology</i> , 2015, 89, 552-567.	1.5	20
147	Rational design and in vivo selection of SHIVs encoding transmitted/founder subtype C HIV-1 envelopes. <i>PLoS Pathogens</i> , 2019, 15, e1007632.	2.1	20
148	Genome-Wide Analysis of Heterogeneous Nuclear Ribonucleoprotein (hnRNP) Binding to HIV-1 RNA Reveals a Key Role for hnRNP H1 in Alternative Viral mRNA Splicing. <i>Journal of Virology</i> , 2019, 93, .	1.5	19
149	Poly(ADP-ribose) potentiates ZAP antiviral activity. <i>PLoS Pathogens</i> , 2022, 18, e1009202.	2.1	19
150	An overview of intracellular interactions between immunodeficiency viruses and their hosts. <i>Aids</i> , 2012, 26, 1243-1254.	1.0	18
151	Cyclin T1 Expression Is Mediated by a Complex and Constitutively Active Promoter and Does Not Limit Human Immunodeficiency Virus Type 1 Tat Function in Unstimulated Primary Lymphocytes. <i>Journal of Virology</i> , 2002, 76, 208-219.	1.5	16
152	Tetherin Inhibits Cell-Free Virus Dissemination and Retards Murine Leukemia Virus Pathogenesis. <i>Journal of Virology</i> , 2017, 91, .	1.5	16
153	Early treatment with a combination of two potent neutralizing antibodies improves clinical outcomes and reduces virus replication and lung inflammation in SARS-CoV-2 infected macaques. <i>PLoS Pathogens</i> , 2021, 17, e1009688.	2.1	16
154	Derivation of simian tropic HIV-1 infectious clone reveals virus adaptation to a new host. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 10504-10509.	3.3	14
155	CLIP-related methodologies and their application to retrovirology. <i>Retrovirology</i> , 2018, 15, 35.	0.9	12
156	Mechanisms of Attenuation by Genetic Recoding of Viruses. <i>MBio</i> , 2021, 12, .	1.8	12
157	Reconstruction of a replication-competent ancestral murine endogenous retrovirus-L. <i>Retrovirology</i> , 2018, 15, 34.	0.9	11
158	Inhibition of spumavirus gene expression by PHF11. <i>PLoS Pathogens</i> , 2020, 16, e1008644.	2.1	11
159	Antibody evolution to SARS-CoV-2 after single-dose Ad26.COVS vaccine in humans. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	10
160	Antibody and Memory B-Cell Immunity in a Heterogeneously SARS-CoV-2-Infected and -Vaccinated Population. <i>MBio</i> , 2022, 13, .	1.8	9
161	An intrinsic host defense against HIV-1 integration?. <i>Journal of Clinical Investigation</i> , 2007, 117, 302-304.	3.9	8
162	Derivation and characterization of an HIV-1 mutant that rescues IP6 binding deficiency. <i>Retrovirology</i> , 2021, 18, 25.	0.9	7

#	ARTICLE	IF	CITATIONS
163	Rhabdo-immunodeficiency virus, a murine model of acute HIV-1 infection. <i>ELife</i> , 2019, 8, .	2.8	6
164	Evaluation of SARS-CoV-2 antibody point of care devices in the laboratory and clinical setting. <i>PLoS ONE</i> , 2022, 17, e0266086.	1.1	6
165	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. <i>Journal of Experimental Medicine</i> , 2022, 219, .	4.2	6
166	VPS29 Exerts Opposing Effects on Endocytic Viral Entry. <i>MBio</i> , 2022, 13, e0300221.	1.8	5
167	Severe Acute Respiratory Syndrome Coronavirus 2 Neutralization After Messenger RNA Vaccination and Variant Breakthrough Infection. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.4	5
168	Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID). <i>Journal of Medical Virology</i> , 1994, 43, 28-32.	2.5	4
169	Repurposing a Bacterial Immune System to Discover Antiviral Targets. <i>New England Journal of Medicine</i> , 2017, 376, 1290-1291.	13.9	3
170	A multimodal antiretroviral protein. <i>Nature Microbiology</i> , 2018, 3, 122-123.	5.9	3
171	Functional Differences between Human and Bovine Immunodeficiency Virus Tat Transcription Factors. <i>Journal of Virology</i> , 2000, 74, 4666-4671.	1.5	3
172	Sensing Retroviruses. <i>Immunity</i> , 2011, 35, 8-10.	6.6	2
173	Comparison of SARS-CoV-2 serological assays for use in epidemiological surveillance in Scotland. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100028.	0.4	2
174	Short Communication: Ultrasensitive Immunoassay for Assessing Residual Simian-Tropic HIV in Nonhuman Primate Models of AIDS. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 473-476.	0.5	0